The Role of IL-15 in Inflammatory Activity of Patients With Rheumatoid Arthritis (RA) Manal A. Bahgat¹ and Hala Gaballah²
|
|
- Ronald Cannon
- 8 years ago
- Views:
Transcription
1 The Role of IL-15 in Inflammatory Activity of Patients With Rheumatoid Arthritis (RA) Manal A. Bahgat¹ and Hala Gaballah² Microbiology &Immunology¹ and Rheumatology & Rehabilitation Departments² Faculty of Medicine Zagazig University Interleukin 15 (IL-15), a new player in the cytokine network, is produced mainly by monocytes and can be detected in the rheumatoid synovium. The aim of this study was to investigate the role of IL- 15 in patients with rheumatoid arthritis (RA). IL-15 cytokine was measured in sera and synovial fluid (SF) of 40 patients with rheumatoid arthritis (RA) and 20 patients with osteoarthritis and only in sera of 20 healthy control using an enzyme-linked immunosorbent method. Seven American College of Rheumatology (ACR) core set measures as well as IL-15 levels were sequentially monitored at the commencement. IL-15 had been detected in sera of 16 (40%) of 40 RA patients, in two (10%) of 20 osteoarthritis (OA) patients and two (10%) of 20 healthy controls. The mean level of circulating IL-15 was significantly higher in RA patients (P < 0 001). In SF, the mean IL-15 levels were significantly higher in RA patients ( 162.8±35.4) than in OA patients ( 32.5±5.5) (P < 0 001). In paired samples (n=40) of sera and SF from RA patients and OA patients, IL-15 levels were higher in the SF than in sera (P < 0 001) in RA but not in OA. Rheumatoid arthritis patients with detectable IL-15 (n=25 ) had higher tender joint scores (P < 0 01), swollen joint scores (P < 0 001) and C-reactive protein (CRP) (P < 0 05), rheumatoid factor (P < 0.001), and long disease duration (P < 0 05) than those without (n=15). In conclusion, IL-15 was elevated significantly in the sera and SF of patients with active rheumatoid arthritis (RA) but not on OA patients and correlated well with several parameters of RA disease activity. These observations suggest that IL-15 production may be associated with an exacerbation of RA, and then IL-15 levels could be useful to assess disease activity. Keywords IL-15, disease activity, rheumatoid arthritis INTRODUCTION RA is an autoimmune disease characterized by the proliferation of synovium and the infiltration of chronic inflammatory cells. Cytokines from synovium and inflammatory cells are thought to be important in the initiation and perpetuation of RA. In particular, macrophage derived cytokines, including tumour necrosis factor alpha (TNFα) and IL-6, have been detected at high levels and many of these monokines function as potent proinflammatory molecules in the joints, and reflect the disease activity of RA (1,2). In the course of the disease, the normal relatively avascular synovium becomes heavily infiltrated by a wide variety of cells, including B cells, macrophages, fibroblasts, neutrophil granulocytes, dendritic cells, and many other cells (3). The synovial lining increases to a thickness of up to 30 cell layers, presumably through influx of macrophages, and by expansion of synovial fibroblasts. The latter produce high amounts of proinflammatory cytokines, mainly TNF, IL-1, and IL-6. Furthermore, many other cytokines such as IL-17, IL-18, and IL-15 chemokines, and angiogenic molecules are present in the inflamed synovial membrane and drive the disease. Subsequently, these proinflammatory cytokines activate signal transduction pathways and transcription factors, which, in turn, control the transcription of cytokines (4). Interleukin-15 (IL-15) is a cytokine produced by macrophages and fibroblast-like synoviocytes. It has a chemoattractant activity, which facilitates recruitment and activation of T-cells (5, 6). IL-15 shares most of the biological activities of IL-2 on several types of lymphocytes, including the proliferation and activation of T, natural killer (NK) and B cells (7). Synovial T cells produced significant amounts of TNF upon incubation with IL-15, but not with IL-2 (8). IL-15 stimulated T cells also elicit TNF production of synovial fluid macrophages in a cell cell contact dependent fashion. In turn, TNF and IL-1 are able to induce IL-15 production in synovial fibroblasts and therefore might perpetuate local T cell proliferation (9). As it has been shown for many other cytokines, IL-15 potently synergizes with other cytokines to enhance T cell growth as well as proliferation 569
2 and macrophage activation. IL-12 and IL-18 in combination with IL-15 promote macrophage activation at low concentrations. Hence, IL-15 is likely to play a role in RA. (10) The cytokine environment in rheumatoid synovium was initially considered to be difficult for T-cell activation and expansion due to the deficiency of IL-2, the factor essential for T-cell growth (11). However, others have shown that IL-15, a novel identified T-cell growth factor was present at significant levels in RA joints. The presence of IL-15 in immunologically active levels in RA synovial fluid provides another mechanism for activation of T-cells, once present within the synovial milieu, which could occur in the presence of relatively low concentrations of IL-2 (5). Therefore, IL-15 should be added to the matrix of cytokines locally produced by fibroblast-i.e. synviocytes (12). The aim of this study was to assess IL-15 levels in the sera and the synovial fluid (SF) of RA patients and correlated it with the clinical and laboratory parameters of rheumatoid arthritis (RA) disease activity. SUBJECTS, MATERIALS AND METHODS This work was conducted in Microbiology & Immunology department and Rheumatology & Rehabilitation Department, Faculty of Medicine Zagazig University in the period from July 2005 to March 2006 on 60 patients who were divided as follow: Patient group (Group I): this group included 40 suffering from rheumatoid arthritis. These subjects fulfilled the 1987 American College of Rheumatology criteria of rheumatoid arthritis (13). The mean age of the RA patients (15 males and 25 females) was 48.3±5.2 years. The mean disease duration was 76 4±20.6 months. Group (IІ): included 20 patients with osteoarthritis. These subjects had clinical and radiological features of Osteoarthritis (OA) according to the criteria of American College of Rheumatology (14). The mean age of the OA patients ( 8 male and 12 females) was 50.4±6.21 years Control group (Group IIІ): this group included 20 normal subjects who were chosen as a control for blood sampling only (no synovial fluid sampling) The mean age of the healthy controls (8 males and 12 females) was 51.1±6.62 years. Oral informed consent was obtained from each patient. All patients included in this study were subjected to the following: Complete history taking, Full clinical examination, Blood sampling, Synovial fluid sampling [except normal control group, no synovial fluid sampling]. Clinical and laboratory assessments: In patients with RA, clinical assessments were performed at commencement by rheumatologist, trained in making standardized assessments. Seven clinical variables (American College of Rheumatology (ACR) core set measures) were evaluated, as defined by the ACR (15) : tender joint count, swollen joint count, pain as recorded on a 100-mm visual analogue scale, physician s global assessment of disease activity, patient s global assessment of disease activity, degree of disability, as measured by a Health Assessment Questionnaire. ALL patients were subjected also to the following: 1-erythrocyte sedimentation rate (ESR). 2- C-reactive protein (CRP) and Rheumatoid factor (RF) which were detected by using latex agglutination test (Avitex-- Latex test, supplied by Omega Diagnostic Limited). Cytokine measurements: Measurement of IL-15 levels in the sera and synovial fluid of RA and OA patients as well as in sera of healthy control by a solid phase sandwich ELISA technique, using the Biosource human IL-15 kit, USA. Principle of the method: The Hu IL-15 kit is a solid phase sandwich Enzyme Linked-Immuno-Sorbent Assay (ELISA). An antibody specific for Hu IL-15 has been coated onto the wells of the microtiter strips provided. Samples, including standards of known Hu IL-15 content, control specimens, and unknowns, are pipetted into these wells, followed by the addition of a biotinylated second antibody. During the first incubation, the Hu IL-15 antigen binds simultaneously to the immobilized (capture) antibody on one site, and to the solution phase biotinylated antibody on a second site. After removal of excess second antibody, Streptavidin-Peroxidase (enzyme) is added. This binds to the biotinylated antibody to complete the four-member sandwich. After a second incubation and washing to remove all the unbound enzyme, a substrate solution is added, which is acted upon by the bound enzyme to produce color. The intensity of this 570
3 colored product is directly proportional to the concentration of Hu IL-15 present in the original specimen. Optical density read at 450 nm using a microplate reader within 30 minutes. The sensitivity of the method (the minimum detectable dose) is <10 pg/ml. Statistical analysis: Statistical analysis was done by using SPSS (Statistical Package for Social Science) statistical software for windows, version 10.The data were presented in the form of mean and standard deviation. Student (t) test was used for comparison of quantitative data. Correlation between two variables was performed using Spear-man s rank correlation coefficient. P < 0 05 was considered statistically significant. RESULTS This study was conducted on two groups of subjects, the patient group (60) which included (40) patients with rheumatoid arthritis (RA), 20 patients with osteoarthritis (OA), and the control group which included 20 healthy volunteers. The results of the study were collected, statistically analyzed and tabulated and illustrated as follows: The demographic data of the studied groups were shown in table (1). There was no significant difference between studied groups in age, gender and duration of disease. In sera, 16 out of 40 RA patients had detectable concentrations of IL-15 (40%), whereas two out of 20 (10%) of the OA patients and two (10%) of the 20 healthy controls had detectable IL-15 (P < 0 001). The mean±sd level of circulating IL-15 was significantly higher in RA patients than in both OA patients and healthy controls (84.8±14.3, 23.5±4.2 and 21.9±3.8 respectively and the P < 0 001) (Table 2). In SF, the number of RA patients with detectable IL-15 in SF were 25 (62.5%) while only 2 patients with OA had detectable concentrations of IL-15 (10%) (P < 0 001). The mean±sd level of IL-15 were also significantly higher in RA patients than in OA patients (162.8±35.4 and 32.5±5.5 respectively and the P< (Table 2). In the paired samples of sera and SF from RA and OA patients, IL-15 levels were significantly higher in the SF than in the sera in RA patients (P < 0 001). However, the levels of IL-15 were not significantly different between the sera and SF in patients with OA.(Table 2) Table (3) shows the correlation between IL- 15 and laboratory & clinical measures of disease activity of patients with active rheumatoid arthritis (RA). Patients with RA (n=40), in whom clinical assessment was performed at base line, were divided into two groups: patients with detectable concentrations of IL-15 (n=25) and those without detectable concentrations of IL-15 (n=15). The above mentioned categories of disease activity of RA were then compared for the two groups. There were no significant differences in pain score, patient s global assessment, physician s global assessment, patient s self-assessed disability, and ESR between the two groups. However, patients with detectable IL-15 had a significant higher tender joint score (P<0 01), swollen joint score (P < 0 001), disease duration (P<0 05), rheumatoid factor (P < 0 001), and CRP (P<0 05), compared with those without. Fig (1) shows highly significant positive correlation between IL-15 levels and tender joint score (r=0 512, P < 0 001). also swollen joints score correlated positively with IL-15 levels (r=0 492, P < 0 001). Fig (2) Table (1): Demographic characteristics in studied groups. RA OA Control P Age (years) 48.3± ± ±6.62 NS Gender Female/male 15/25 12/8 12/8 NS Disease duration 76.4± ± NS NS= Not significant. 571
4 Table (2): Levels of IL-15 in patients with RA and osteoarthritis (OA) and healthy control IL-15 pg/ml RA (n=40) OA (n=20) Control (n=20) P Sera positivity (%) 16 (40%) 2 (10%) 2 (10%) <0.001 Mean±SD 84.8±14.3* 23.5± ±3.8 <0.001 Synovial Fluid Positivity (%) 25 (62.5%) 2 (10%) <0.001 Mean±SD 162.8± ±5.5 <0.001 Table (3): Comparison of clinical and laboratory parameters between patients with detectable IL-15 and those without Variables Patients with detectable IL-15 (n=25) Patients without detectable IL-15 (n=15) Disease duration (months) 80.2± ±16.8 <0.05 Tender joint score* 17±6 11±3 <0.01 Swollen joint score* 14±4 6±2 <0.001 Visual analogue pain scale (mm) 52± ±14 NS Physician s global assessment 5.1± ±1.6 NS Patient s global assessment 5.0± ±2.3 NS Degree of disability 1.7± ±0.5 NS ESR (mm/h) 45.5± ±11 NS C-reactive protein 24 (96%) 11 (73.3%) <0.05 Rheumatoid factor 25 (100%) 10 (66.7%) <0.001 * Mean±SD Positive cases. NS= Not significant. 35 P Tender joint score r=0.512, p< IL-15 (pg/ml) Fig (1): Correlation of IL-15 with tender joint score. 572
5 Swollen joint score r=0.492, p< IL-15 (pg/ml) Fig (2): Correlation of IL-15 with Swollen joint score. DISCUSSION Rheumatoid arthritis (RA) is a chronic inflammatory disease that associated with intense pain, irreversible joint destruction, systemic complications and a progressive functional decline. The disease is also associated with a decreased life expectancy of five to 15 years secondary to comorbid illnesses that may be exacerbated by the underlying pathophysiologic mechanisms. It is an immune mediated disease that develops in a genetically predisposed host. It is characterized by development of a hyperplastic synovial membrane (i.e. pannus) that has been infiltrated by B-cells and macrophages, which lead to the production and release of proinflammatory cytokines. In diseases such as RA, an imbalance develops between the proinflammatory cytokines (i.e. interleukin (IL)-1b, tumor necrosis factor-a (TNF-a, IL-6, IL-15)) and the anti inflammatory cytokines (i.e., soluble TNF receptors, IL-1 receptor antagonists) (16). Involvement of IL-15 has been demonstrated in a number of autoimmune and infectious diseases, such as rheumatoid arthritis, sarcoidosis and leprosy, i.e. diseases where cellular immunity predominates (5, 17). IL-15 is a potent T-cell attractant that is elevated in synovial fluid and synovial membranes in patients with RA. Some preliminary studies suggest this cytokine is involved in the perpetuation of RA synovitis (18). In the present study IL-15 levels were significantly higher in sera of patients with RA than those of patients with OA or healthy controls, which confirms previous reports. Who found that RA patients had significantly higher serum levels of IL-15 ( /- 150 pg/ml; p = ) than systemic lupus erythematosus (SLE), patients (9.8 +/ pg/ml), spondyloarthro- pathies (SSd) patients (7.9 +/ pg/ml) and healthy donors' (5.2 +/ pg/ml) (18). By comparison between RA and OA Synovial fluid values, we found that RA synovial fluid level of IL-15 highly exceeded that estimated in SF of OA patients. This finding coincides with McInnes et al. (5, 8) and Thurkow et al. (19). Who were reported that IL-15 expressed at high concentrations in synovial fluid (SF) and ST from patients with RA. further suggesting that IL-15 is an important regulator of the inflammation in RA. They concluded that IL-15 probably contributes to the chronic inflammat- ory process in patients with RA. Ziolkowska et al (20), also reported that synovial fluids of patients with rheumatoid arthritis, but not with osteoarthritis, contain high levels of IL-15 and IL-17. In addition, in paired samples of the sera and SF, the study revealed that IL-15 levels were significantly higher in SF than sera in patients with RA, but there was no significant difference in patients with OA. This in 573
6 agreement with Fahmy et al (21), how revealed that the synovial fluid of RA patients had a significant elevated level of IL-15 than that estimated in the serum. In the present study there was a significant difference in disease duration between RA patients with detectable levels of IL-15 and those without. This in agreement with Gonzalez-Alvaro (18). who reported that RA patients with a disease evolution less than 2 years showed lower IL-15 levels (33.7 +/ pg/ml) than those with long-term disease ( / pg/ml; p = 0.004)(18). We demonstrated that patients with detectable levels of IL-15 in had higher tender joint scores, swollen joint scores, RF and CRP. Moreover, IL-15 levels correlated well with several parameters indicative of disease activity in RA, especially with the tender and swollen joint scores. There were significant positive correlations between; levels of IL-15,and both tender joint score and swollen joint score in RA patient. Our finding coincided with other investigator how reported that there was a relationship (p < 0.01) between the concentrations of TNFalpha, IL-12, IL-15, and IL-18 cytokines in blood and synovial fluid with the quantity of the disease activity score in joints. Also they concluded that cytokines concentrations could be good indicators of the degree of the general activity of RA and could contribute to the interpretation of insufficiently well known views of the pathogenesis role and significance of cytokines in an active disease (22). In conclusion, IL-15 was elevated significantly in the sera and SF of patients with active rheumatoid arthritis (RA) but not on OA patients and correlated well with several parameters of RA disease activity. These observations suggest that IL-15 production may be associated with an exacerbation of RA, and then circulating IL- 15 levels could be useful to assess disease activity. REFERENCES 1- Brennan FM, Maini RN, Feldmann M (1992): TNF-alpha: pivotal role in rheumatoid arthritis? Br J Rheumatol. 31: Ito A, Itoh Y, Sasaguri Y, Morimatsu M, Mori Y (1992): Effects of interleukin-6 on the metabolism of connective tissue components in rheumatoid synovial fibroblasts. Arthritis Rheum. 35: Haraoui, B., J.P. Pelletier, J.M. Cloutier, et al. (1991): Synovial membrane histology and immuno- pathology in rheumatoid arthritis and osteoarthritis. In vivo effects of antirheumatic drugs. Arthritis Rheum. 34: Sweeney, S.E. & G.S. Firestein. (2004): Rheumatoid arthritis: regulation of synovial inflammation. Int. J. Biochem. Cell Biol. 36: McInnes, I.B.; AlMughales, J.; Field, M.; Leung, B.P. and Huang, F.P.(1996): The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med.; 2: Harada, S.; Yamamura, M.; Okamoto, M.; Morita, Y.; Kawashima, M.;Aita, and Makino, M. (1999): production of interleukin 7 and interleukin-15 by fibroblast like synoviocytes from patients with rheumatoid arthritis. Arth. Rheum.; 72: Ogata, Y.; Kukita, A.; Kukita, T.; Komine, H. Miyahava, A.; Miyazaki, S. and Kohashi, O. (1999): A novel role of IL-2 J. in the development of osteoclasts Inability to replace its activity with IL-2. J. Immunol.; 162: McInnes, I.B., B.P. Leung, R.D. Sturrock, et al. (1997): Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-alpha production in rheumatoid arthritis. Nat. Med. 3: Miranda-Carus, M.E., A. Balsa, M. Bentto- Miguel, et al. (2004): IL-15 and the initiation of cell contact-dependent synovial fibroblast-t lymphocyte crosstalk in rheumatoid arthritis: effect of methotrexate. J. Immunol. 173: Gracie, J.A., R.J. Forsey, W.L. Cham, et al. (1999): A proinflammat- ory role for IL-18 in rheumatoid arthritis. J. Clin. Invest. 104: Firestein, G.S.; Alvaro-Gracia, J.M. and Maki, R. (1990): Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol.;144: McInnes, I.B. and Liew, F.Y. (1998): Interleukin-15, a proinflamma- tory role in 574
7 rheumatoid arthritis synovitis. Immunol. Today; 19: Arnett, F.C; Edworthy, S.M.; Bloch, D.A.; McShane, D.Z.; Fries, J.F. et al.(1988): The American Rheumatism Association (1987), Revised criteria forthe classification of rheumatoid arthritis. Arth. Rheum; 31: Altman, R.; Alarcon, G.; Appeelrouth, D. et al (1991): The American College of Rheumatology Criteria for the classification and reporting of osteoarthritis of the hip. Arthritis. Rheum., 34: Felson DT, Anderson JJ, Boers M et al.(1993): The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum; 36: Goronzy JJ, Weyand CM.(2001): Rheumatoid arthritis: epidemiology, pathology, and pathogenesis. In: Klippel JH, Crofford LJ, Stone JH, Weyand, CM, eds. Primer on the Rheumatic Diseases. 12th ed. Atlanta: Arthritis Foundation.: Jullien D, Sieling PA, Uyemura K, Mar ND, Rea TH, Modlin RL.(1997): IL-15, an immunomodulator of T cell responses in intracellular infection. J Immunol; 158: Gonzalez-Alvaro I., Ortiz AM, Garcia- Vicuna R. et al (2003): Increased serum levels of interleukin-15 in rheumatoid arthritis with long- term disease. Clinical & Experimental Rheumatology. 21(5): Thurkow E.W., Vander Heijden I.M., Breedveld F.C. et al. (1997). Increased expression of IL-15 in the synovium of patients with rheumatoid arthritis compared with patients with yersiniainduced arthritis and osteoarthritis. J Pathol 181,: Ziolkowska M, Anna Koc, Grazyna Luszczykiewicz, Krystyna Ksiezopolska- Pietrzak et al (2000): High Levels of IL-17 in Rheumatoid Arthritis Patients: IL- 15Triggers In Vitro IL-17 Production Via CyclosporinA Sensitive Mechanism The Journal of Immunology, 164: Fahmy S; Nahed M. Sherif; Mervat A. Reda and Mona G. El Houseiny (2004): Interleukin 15 Levels in Different Rheumatic Diseases. Sci. Med. J. ESCME, Vol. 16, No. 1, Jan. 22- Petrovic-Rackov L. (2006): Evaluation of the degree of clinical rheumatoid arthritis activity based on the concentrations of cytokines TNF-alpha, IL-12, IL-15, and IL-18 in serum and synovial fluid. Vojnosanit Pregl. Jan;63(1):
8 دور الا نترلوكين الملخص العربي ١٥ في النشاط الالتهابي لمرضى الالتهاب المفصلي الرثياني ٢ ١ منال عبد التواب بهجت و هاله جاب االله ٢ ١ قسم الميكروبيولوجيا والمناعة وقسم الروماتيزم والتا هيل - كلية الطب- جامعة الزقازيق يشكل الا نترلوكين ١٥ جزء جديد من ا جزاء شبكة السيتوكين و تعد الخلايا الاحاديه المنتج الري يسي له و من الممكن الكشف عنه في الغشاء الزليلي لمرضى الالتهاب المفصلي الرثياني. الهدف من هذه الدراسة تقييم ا همية ودور الا نترلوكين ١٥ في مرضى الالتهاب المفصلي الرثيانى تم قياس مستوى الا نترلوكين ١٥ في الا مصال و الساي ل الزلالى ل ٤٠ من مرضى الالتهاب المفصلي الرثيانى و ٢٠ من مرضى الفصال العظمى و في ا مصال ٢٠ من الا صحاء كمجموعة ظابطة وذلك باستخدام طريقة الاليزا.وقد تم قياس مدى المرض باستعمال القواعد السبع للقياس تبعا للكلية الملكية الا مريكية للروماتيزم و مستوى الا نترلوكين ١٥ في ذات الوقت. تم الكشف عن الا نترلوكين ١٥ في ا مصال ١٦ من (٤٠%) ٤٠ من مرضى الالتهاب المفصلي الرثيانى و ٢ من (١٠%) ٢٠ من مرضى الفصال العظمى و ٢ من (١٠%) ٢٠ من الا صحاء. ووجد ا ن متوسط الا نترلوكين ١٥ في ا مصال مرضى الالتهاب المفصلي الرثيانى ا على ا حصاي يا من المجموعات الا خرى. بالنسبة للساي ل الزلالى وجد ا ن مستوى الا نترلوكين ١٥ مرتفع ا حصاي يا في مرضى الالتهاب المفصلي الرثيانى عن مرضى الفصال العظمى. وفي العينات الزوجية (٤٠) من الا مصال و الساي ل الزلالي وجد ا ن مستوى الا نترلوكين ١٥ مرتفع ا حصاي يا في الساي ل الزلالي عن الا مصال في مرضى الالتهاب المفصلي الرثيانى وغير مرتفع في مرضى الفصال العظمى. كما وجدت علاقة ذات دلالة ا حصاي ية بين تركيز الا نترلوكين وكل من معدل الا لم بالمفصل و درجة التورم بالمفصل و وجود البروتين التفاعلي س والعامل الرثياني بالا ضافة لطول فترة المرض. ونستنتج من ذلك ا ن الا نترلوكين ١٥ يرتفع في الا مصال والساي ل الزلالي لمرضى الالتهاب المفصلي الرثيانى ولا يرتفع في مرضى الفصال العظمى. كما ا ن هناك علاقة ذات دلالة ا حصاي ية بين مستوى الا نترلوكين ١٥ وعدد من دلالات النشاط لمرضى الالتهاب المفصلي الرثيانى. ومن هذه المشاهدات نجد ا ن الا نترلوكين ١٥ قد يصاحب زيادة حدة المرض ومن ثم قد يفيد في قياس درجة نشاط المرض. 576
The Most Common Autoimmune Disease: Rheumatoid Arthritis. Bonita S. Libman, M.D.
The Most Common Autoimmune Disease: Rheumatoid Arthritis Bonita S. Libman, M.D. Disclosures Two googled comics The Normal Immune System Network of cells and proteins that work together Goal: protect against
More informationEffect of Methotrexate on Serum Levels of IL-1α and IL-8 in Rheumatoid Arthritis
THE RHEUMATOID IRAQI POSTGRADUATE ARTHRITIS MEDICAL JOURNAL VOL.12, NO. 3,2013 Effect of Methotrexate on Serum Levels of IL-1α and IL-8 in Rheumatoid Arthritis Ahmed A. Al-Hassan*, Mohammed O. Hamzah**,
More informationRheumatoid arthritis: an overview. Christine Pham MD
Rheumatoid arthritis: an overview Christine Pham MD RA prevalence Chronic inflammatory disease affecting approximately 0.5 1% of the general population Prevalence is higher in North America (approaching
More informationA Genetic Analysis of Rheumatoid Arthritis
A Genetic Analysis of Rheumatoid Arthritis Introduction to Rheumatoid Arthritis: Classification and Diagnosis Rheumatoid arthritis is a chronic inflammatory disorder that affects mainly synovial joints.
More informationImmune modulation in rheumatology. Geoff McColl University of Melbourne/Australian Rheumatology Association
Immune modulation in rheumatology Geoff McColl University of Melbourne/Australian Rheumatology Association A traditional start to a presentation on biological agents in rheumatic disease is Plasma cell
More informationRheumatoid Arthritis. Emily Relles. Copyright May, 2014, Emily Relles and Koni Stone
Rheumatoid Arthritis Emily Relles Copyright May, 2014, Emily Relles and Koni Stone Rheumatoid Arthritis (RA) is an autoimmune disease that affects 0.5-1% of adults in industrialized countries and is caused
More informationRheumatology Labs for Primary Care Providers. Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine
Rheumatology Labs for Primary Care Providers Robert Monger, M.D., F.A.C.P. 2015 Frontiers in Medicine Objectives Review the Indications for and Interpretation of lab testing for the following diseases:
More informationANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE
ANTIBODIES AGAINST CITRULLINATED PEPTIDES IN EARLY RHEUMATOID ARTHRITIS: DIAGNOSTIC AND PROGNOSTIC SIGNIFICANCE Principal investigators: Dr Raimon Sanmartí Sala Hospital Clínic i Provincial de Barcelona
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 December 2003 CPMP/EWP/556/95 rev 1/Final COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
More informationA LTCI Approach to Managing Rheumatoid Arthritis
A LTCI Approach to Managing Rheumatoid Arthritis A bit of Science, a bit of Art, a lot of Perseverance... Stephen K. Holland, MD Senior Vice President & Medical Director Long Term Care Group, Inc. Long
More informationClinically Actionable Biomarkers in Rheumatoid Arthritis
Clinically Actionable Biomarkers in Rheumatoid Arthritis PepTalk January 6, 2009 William Robinson, MD, PhD Stanford University School of Medicine VA Palo Alto Health Care System T cell mediated Autoimmune
More informationBIOM 255 - Firestein, Winter 2009. Rheumatoid arthritis. Page 1
Rheumatoid arthritis Page 1 Vascular events in RA Synovium in rheumatoid arthritis Non-extra articular RA Extra articular RA Turesson, et al. Ann Rheum Dis. 2007;66:60 Normal Rheumatoid Arthritis Major
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationELISA BIO 110 Lab 1. Immunity and Disease
ELISA BIO 110 Lab 1 Immunity and Disease Introduction The principal role of the mammalian immune response is to contain infectious disease agents. This response is mediated by several cellular and molecular
More informationChanges in synovial inflammation over time in rheumatoid arthritis
Chapter 7 Changes in synovial inflammation over time in rheumatoid arthritis M van Oosterhout, I Bajema, REM Toes, TWJ Huizinga, JM van Laar Submitted Ann Rheum Dis Chapter 7 Abstract Objectives To investigate
More informationRheumatoid Arthritis. Disease RA Final.indd 2 15. 6. 10. 11:23
Rheumatoid Arthritis Disease RA Final.indd 2 15. 6. 10. 11:23 Understanding what to expect can help you prepare for your transition into treatment. Rheumatoid Arthritis What You Need To Know About Rheumatoid
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure
More informationMedia Release. Basel, 11 June 2009. RA patients with enhanced response identified
Media Release Basel, 11 June 2009 New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients
More informationTreatment of Rheumatoid Arthritis in the New Millennium. Neal I. Shparago, D.O., FACP, FACR
Treatment of Rheumatoid Arthritis in the New Millennium Neal I. Shparago, D.O., FACP, FACR What is RA? Symmetric inflammatory polyarthritis Rheumatoid factor positive in 80% Anti-CCP positive in approximately
More informationBiologic Treatments for Rheumatoid Arthritis
Biologic Treatments Rheumatoid Arthritis (also known as cytokine inhibitors, TNF inhibitors, IL 1 inhibitor, or Biologic Response Modifiers) Description Biologics are new class of drugs that have been
More informationspecific B cells Humoral immunity lymphocytes antibodies B cells bone marrow Cell-mediated immunity: T cells antibodies proteins
Adaptive Immunity Chapter 17: Adaptive (specific) Immunity Bio 139 Dr. Amy Rogers Host defenses that are specific to a particular infectious agent Can be innate or genetic for humans as a group: most microbes
More informationRHEUMATOID ARTHRITIS. Dr Bruce Kirkham Rheumatology Clinical Lead
RHEUMATOID ARTHRITIS Dr Bruce Kirkham Rheumatology Clinical Lead RHEUMATOID ARTHRITIS (RA) RA is a common disease: 0.8 per cent of the population RA more common in females: female to male ratio 3:1 RA
More informationIgE (Human) ELISA Kit
IgE (Human) ELISA Kit Catalog Number KA0216 96 assays Version: 03 Intended for research use only www.abnova.com Table of Contents Introduction... 3 Intended Use... 3 Background... 3 Principle of the Assay...
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationB Cells and Antibodies
B Cells and Antibodies Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School Lecture outline Functions of antibodies B cell activation; the role of helper T cells in antibody production
More informationMedical Policy Manual. Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014
Medical Policy Manual Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014 Section: Laboratory Last Reviewed Date: June 2014 Policy No: 67 Effective Date: September 1, 2014 IMPORTANT
More informationRheumatoid Arthritis. Nicole Klett,, M.D.
Rheumatoid Arthritis Nicole Klett,, M.D. Rheumatoid Arthritis Systemic Chronic Inflammatory Primarily targets the synovium of diarthrodial joints Etiology likely combination genetic and environmental Diarthrodial
More informationSome Immunological Test. Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras
Some Immunological Test Presented by Alaa Faeiz Ashwaaq Dyaa Aseel Abd AL-Razaq Supervised by D.Feras Alaa Faeiz Antigen -Antibody Reactions. Antigen antibody reactions are performed to determine the presence
More informationDr Sarah Levy Consultant Rheumatology Croydon University Hospital
Dr Sarah Levy Consultant Rheumatology Croydon University Hospital Contents Definition/ epidemiology Diagnosis Importance of early diagnosis/ treatment Guidelines Evidence based treatment protocol Current
More informationCoxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation
Coxib s have taught us a lesson to explore more diligently the molecular and cellular pathways of inflammation Steffen Gay Arthritis linked to cardiovascular disease CV Death Osteoarthritis CHF Rheumatoid
More informationImmunological studies on Rheumatoid Arthritis treated with Homeopathic drugs: Results of the Pilot Study
EXTRA MURAL RESEARCH Immunological studies on Rheumatoid Arthritis treated with Homeopathic drugs: Results of the Pilot Study Prakash Rao 1 * & Nagalakshmi Prasanna M 2 1 Clinical Research Unit (Homoeopathy)
More informationNatalia Taborda Vanegas. Doc. Sci. Student Immunovirology Group Universidad de Antioquia
Pathogenesis of Dengue Natalia Taborda Vanegas Doc. Sci. Student Immunovirology Group Universidad de Antioquia Infection process Epidermis keratinocytes Dermis Archives of Medical Research 36 (2005) 425
More informationPPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines
PPAR-γ agonist pioglitazone affects rat gouty arthritis by regulating cytokines R.-C. Wang and D.-M. Jiang Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing,
More informationVectra DA Blood Test for Rheumatoid Arthritis. Original Policy Date January /2014
MP 2.04.81 Vectra DA Blood Test for Rheumatoid Arthritis Medical Policy Section 2.0 Original Policy Date January /2014 Last Review Status/Date 1/2014 Disclaimer Our medical policies are designed for informational
More informationRheumatoid Arthritis
Rheumatoid Arthritis While rheumatoid arthritis (RA) has long been feared as one of the most disabling types of arthritis, the outlook has dramatically improved for many newly diagnosed patients. Certainly
More informationIMMUNOPATHOGENESIS OF. Immunology Division School of Pathology NHLS & University of the Witwatersrand 082 807 2628
IMMUNOPATHOGENESIS OF RHEUMATOID ARTHRITIS Prof AA Wadee Immunology Division School of Pathology NHLS & University of the Witwatersrand 082 807 2628 Objectives Distinguish i between type III and type IV
More informationEtanercept (Enbrel ) in Patients with Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in Disability
Etanercept (Enbrel ) in Patients with Rheumatoid Arthritis with Recent Onset Versus Established Disease: Improvement in Disability SCOTT W. BAUMGARTNER, ROY M. FLEISCHMANN, LARRY W. MORELAND, MICHAEL H.
More informationALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES
ALLIANCE FOR LUPUS RESEARCH AND PFIZER S CENTERS FOR THERAPEUTIC INNOVATION CHALLENGE GRANT PROGRAM PROGRAM GUIDELINES DESCRIPTION OF GRANT MECHANISM The Alliance for Lupus Research (ALR) is an independent,
More informationChapter 43: The Immune System
Name Period Our students consider this chapter to be a particularly challenging and important one. Expect to work your way slowly through the first three concepts. Take particular care with Concepts 43.2
More informationNew Evidence reports on presentations given at EULAR 2012. Rituximab for the Treatment of Rheumatoid Arthritis
New Evidence reports on presentations given at EULAR 2012 Rituximab for the Treatment of Rheumatoid Arthritis Report on EULAR 2012 presentations Long-term safety of rituximab: 10-year follow-up in the
More informationA New Era in Rheumatoid Arthritis Treatment
A New Era in Rheumatoid Arthritis Treatment Jill C. Costello, MD; Paul B. Halverson, MD ABSTRACT Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily manifests as a chronic symmetric
More informationHiPer RA Test Teaching Kit
HiPer RA Test Teaching Kit Product Code: HTI019 Number of experiments that can be performed: 20 Duration of Experiment: 1hour Storage Instructions: The kit is stable for 6 months from the date of receipt
More informationEvidence-based Management of Rheumatoid Arthritis (2009)
CPLD reviews its distance learning programmes every twelve months to ensure currency. This update has been produced by an expert and should be read in conjunction with the Evidencebased Management of distance
More informationANIMALS FORM & FUNCTION BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES. Animals Form & Function Activity #4 page 1
AP BIOLOGY ANIMALS FORM & FUNCTION ACTIVITY #4 NAME DATE HOUR BODY DEFENSES NONSPECIFIC DEFENSES PHYSICAL BARRIERS PHAGOCYTES Animals Form & Function Activity #4 page 1 INFLAMMATORY RESPONSE ANTIMICROBIAL
More informationCHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS
CHAPTER 2 ANTIGEN/ANTIBODY INTERACTIONS See APPENDIX (1) THE PRECIPITIN CURVE; (2) LABELING OF ANTIBODIES The defining characteristic of HUMORAL immune responses (which distinguishes them from CELL-MEDIATED
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Biochemistry The Master Degree in Medical Laboratory Sciences /Clinical Biochemistry, is awarded by the Faculty of Graduate Studies
More informationDISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY
ORIGINAL ARTICLES DISEASE COURSE IN EARLY RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY Teodora Serban 1,2, Iulia Satulu 2, Oana Vutcanu 2, Mihaela Milicescu 1,2, Carina Mihai 1,2, Mihai Bojinca 1,2, Victor
More informationwww.gbo.com/bioscience Tissue Culture 1 Cell/ Microplates 2 HTS- 3 Immunology/ HLA 4 Microbiology/ Bacteriology Purpose Beakers 5 Tubes/Multi-
11 Cryo 5 Tubes/Multi 2 HTS 3 Immunology / Immunology Technical Information 3 I 2 96 Well ELISA 3 I 4 96 Well ELISA Strip Plates 3 I 6 8 Well Strip Plates 3 I 7 12 Well Strip Plates 3 I 8 16 Well Strip
More informationTopic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA.
Topic: Serological reactions: the purpose and a principle of reactions. Agglutination test. Precipitation test. CFT, IFT, ELISA, RIA. Serology is the study and use of immunological tests to diagnose and
More informationEnvironmental, genetic and immunological determinants of Rheumatoid Arthritis
University of Zurich University Hospital of Zurich Environmental, genetic and immunological determinants of Rheumatoid Arthritis FORALLVENT Symposium Basel, 2007 Diego Kyburz, M.D. Division of Rheumatology
More informationRayBio Human TNF-alpha
RayBio Human TNF-alpha ELISA Kit User Manual (Revised Mar 1, 2012) RayBio Human TNF-alpha ELISA Kit Protocol (Cat#: ELH-TNFalpha-001) RayBiotech, Inc. We Provide You With Excellent Protein Array System
More informationHow Does a Doctor Test for AIDS?
Edvo-Kit #S-70 How Does a Doctor Test for AIDS? S-70 Experiment Objective: The Human Immunodefi ciency Virus (HIV) is an infectious agent that causes Acquired Immunodefi ciency Syndrome (AIDS) in humans.
More information2) Macrophages function to engulf and present antigen to other immune cells.
Immunology The immune system has specificity and memory. It specifically recognizes different antigens and has memory for these same antigens the next time they are encountered. The Cellular Components
More informationRheumatoid Arthritis Information
Rheumatoid Arthritis Information Definition Rheumatoid arthritis (RA) is a long-term disease that leads to inflammation of the joints and surrounding tissues. It can also affect other organs. Alternative
More informationCourse Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology
Course Curriculum for Master Degree in Medical Laboratory Sciences/Clinical Microbiology, Immunology and Serology The Master Degree in Medical Laboratory Sciences / Clinical Microbiology, Immunology or
More informationRheumatoid Arthritis
Rheumatoid Arthritis Carole Callaghan Principal Pharmacist NHS Lothian Aim To update pharmacists on the current management of rheumatoid arthritis and explore ways to implement pharmaceutical care for
More informationDrug Development Services
Drug Development Services USING BLOOD AND BONE MARROW PRIMARY CELL SYSTEMS Clinically Relevant In Vitro Assays Broad Spectrum of Drug Classes Multi-Species Platforms Enhancing Drug Development through
More informationRayBio Human IL-8 ELISA Kit
RayBio Human IL-8 ELISA Kit User Manual (for Cell Lysate and Tissue Lysate) (Revised Mar 1, 2012) RayBio Human IL-8 ELISA Kit Protocol (Cat#: ELH-IL8-001C) RayBiotech, Inc. We Provide You With Excellent
More informationTREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY. Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine
TREATING AUTOIMMUNE DISEASES WITH HOMEOPATHY Dr. Stephen A. Messer, MSEd, ND, DHANP Professor and Chair of Homeopathic Medicine AUTOIMMUNE DISEASES An autoimmune disorder occurs when the body s immune
More informationALPHA (TNFa) IN OBESITY
THE ROLE OF TUMOUR NECROSIS FACTOR ALPHA (TNFa) IN OBESITY Alison Mary Morris, B.Sc (Hons) A thesis submitted to Adelaide University for the degree of Doctor of Philosophy Department of Physiology Adelaide
More informationAutoimmunity and immunemediated. FOCiS. Lecture outline
1 Autoimmunity and immunemediated inflammatory diseases Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline Pathogenesis of autoimmunity: why selftolerance fails Genetics of autoimmune diseases Therapeutic
More informationThe role of IBV proteins in protection: cellular immune responses. COST meeting WG2 + WG3 Budapest, Hungary, 2015
The role of IBV proteins in protection: cellular immune responses COST meeting WG2 + WG3 Budapest, Hungary, 2015 1 Presentation include: Laboratory results Literature summary Role of T cells in response
More informationREVIEW ARTICLE Immunopathogenesis and Treatment of Rheumatoid Arthritis: Recent Developments ABSTRACT
REVIEW ARTICLE Immunopathogenesis and Treatment of Rheumatoid Arthritis: Recent Developments ASM Giasuddin 1, KA Jhuma 2, AMM Haq 3, MM Haque 3 1 Dept of Biochemistry & Immunology, State College of Health
More informationMouse IFN-gamma ELISpot Kit
Page 1 of 8 Mouse IFN-gamma ELISpot Kit Without Plates With Plates With Sterile Plates Quantity Catalog Nos. 862.031.001 862.031.001P 862.031.001S 1 x 96 tests 862.031.005 862.031.005P 862.031.005S 5 x
More informationABOUT RHEUMATOID ARTHRITIS
MEDIA BACKGROUNDER ABOUT RHEUMATOID ARTHRITIS Rheumatoid arthritis (RA) is a type of arthritis (chronic inflammatory polyarthritis) that typically affects hands and feet, although any joint in the body
More informationMedical Policy Anti-CCP Testing for Rheumatoid Arthritis
Medical Policy Anti-CCP Testing for Rheumatoid Arthritis Table of Contents Policy: Commercial Coding Information Information Pertaining to All Policies Policy: Medicare Description References Authorization
More informationCytokinic panel in rheumatoid arthritis and correlation with histological patterns of synovitis active type of disease
Romanian Journal of Morphology and Embryology 25, 46(2):87 92 Cytokinic panel in rheumatoid arthritis and correlation with histological patterns of synovitis active type of disease CARMEN AVRĂMESCU 1),
More informationIn vitro co-culture model of the inflamed intestinal mucosa
In vitro co-culture model of the inflamed intestinal mucosa Berlin, December 13, 2011 Eva-Maria Collnot, e.collnot@mx.uni-saarland.de Helmholtz Institute for Pharmaceutical Research Saarland Departement
More informationOnce the immune system is triggered, cells migrate from the blood into the joints and produce substances that cause inflammation.
HealthExchange Points For Your Joints An Arthritis Talk Howard Epstein, MD Orthopaedic & Rheumatologic Institute Rheumatic & Immunologic Disease Cleveland Clinic Beachwood Family Health & Surgery Center
More informationModelling and analysis of T-cell epitope screening data.
Modelling and analysis of T-cell epitope screening data. Tim Beißbarth 2, Jason A. Tye-Din 1, Gordon K. Smyth 1, Robert P. Anderson 1 and Terence P. Speed 1 1 WEHI, 1G Royal Parade, Parkville, VIC 3050,
More informationSYNOPSIS. 2-Year (0.5 DB + 1.5 OL) Addendum to Clinical Study Report
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier (For National Authority Use
More informationArthritis in Children: Juvenile Rheumatoid Arthritis By Kerry V. Cooke
Reading Comprehension Read the following essay on juvenile rheumatoid arthritis. Then use the information in the text to answer the questions that follow. Arthritis in Children: Juvenile Rheumatoid Arthritis
More informationSymptoms ongoing for 6/12, initially intermittent in nature.
Rheumatoid Arthritis Case Study INTRODUCTION Each student will have watched the relevant MDT member carrying out their initial assessment on the same newly diagnosed Rheumatoid Arthritis patient. Videos
More informationNURS 821 Alterations in the Musculoskeletal System. Rheumatoid Arthritis. Type III Hypersensitivity Response
NURS 821 Alterations in the Musculoskeletal System Margaret H. Birney PhD, RN Lecture 12 Part 2 Joint Disorders (cont d) Rheumatoid Arthritis Definition: Autoimmune disorder occurring in genetically sensitive
More informationRoche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy
Media Release Basel, 6 June 2012 Roche s RoACTEMRA improved rheumatoid arthritis signs and symptoms significantly more than adalimumab as single-agent therapy Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced
More information(Intro to Arthritis with a. Arthritis) Manager of Education & Services for the Vancouver Island Region of The Arthritis Society
Arthritis 101 (Intro to Arthritis with a Focus on Rheumatoid Arthritis) by Cari Taylor by Cari Taylor Manager of Education & Services for the Vancouver Island Region of The Arthritis Society What You Will
More informationInflammation, Rheumatoid Arthritis and Cytokines
Inflammation, Rheumatoid Arthritis and Cytokines Rheumatoid arthritis (RA) is the commonest inflammatory joint disease with considerable morbidity and mortality. Conventional disease-modifying antirheumatic
More informationRheumatoid Arthritis www.arthritis.org.nz
Rheumatoid Arthritis www.arthritis.org.nz Did you know? Rheumatoid arthritis (RA) is the third most common form of arthritis Approximately 40,000 New Zealanders have RA RA can occur at any age, but most
More information27E10: A unique monoclonal antibody against MRP8/14 (S100A8/A9, Calprotectin)
BMA BIOMEDICALS Rheinstrasse 28-32 CH-4302 Augst (Switzerland) Phone:+41 61 811 6222 Fax: +41 61 811 6006 info@bma.ch www.bma.ch 27E10: A unique monoclonal antibody against MRP8/14 (S100A8/A9, Calprotectin)
More informationStaph Protein A, Immune Complexes, Cryoglobulins, and the Treatment of Rheumatoid Arthritis:
Staph Protein A, Immune Complexes, Cryoglobulins, and the Treatment of Rheumatoid Arthritis: Immunomodulation, not Immunosuppression Written by Craig Wiesenhutter, M.D. January 2016 This paper has been
More informationAutoimmunity. Autoimmunity. Genetic Contributions to Autoimmunity. Targets of Autoimmunity
Autoimmunity Factors predisposing an individual to autoimmune disease Mechanisms of initiation of autoimmunity Pathogenesis of particular autoimmune disease Animal models of autoimmune disease Treatment
More informationOutline. Personal profile & research interests. Rheumatology research in Ireland. Current standing. Future plans
Outline Personal profile & research interests Rheumatology research in Ireland Current standing Future plans Personal profile 1983 MB Queens University 1990-3 ARUK Clinical Research Fellowship 1990-93
More informationIn the last decade, there have been major changes in the
233 Promising New Treatments for Rheumatoid Arthritis The Kinase Inhibitors Yusuf Yazici, M.D., and Alexandra L. Regens, B.A. Abstract Three major advances over the last decade have impacted the way we
More informationInflammatory Cytokine-induced Expression of Vasohibin-1 by Rheumatoid Synovial Fibroblasts
9 6 6 958 Inflammatory Cytokine-induced Expression of Vasohibin- by Rheumatoid Synovial Fibroblasts a b c a a a a d e a* a a b c d e 5 6 6 9 5 56 67 7 ʼ ʼ ʼ ʼ ʼ ʼ ʼ ʼ 5 6 6 ʼ 5 75 989 6 69 8 95 56 56896
More informationThe Association between Osteoarthritis of the Knee Joint and Chronic Venous Insufficiency of the Legs. Wameedh R S Al-Omari, FRCP*
Bahrain Medical Bulletin, Vol. 4, No. 1, March 2012 The Association between Osteoarthritis of the Knee Joint and Chronic Venous Insufficiency of the Legs Wameedh R S Al-Omari, FRCP* Background: The possible
More informationChapter 6: Antigen-Antibody Interactions
Chapter 6: Antigen-Antibody Interactions I. Strength of Ag-Ab interactions A. Antibody Affinity - strength of total noncovalent interactions between single Ag-binding site on an Ab and a single epitope
More informationHuCAL Custom Monoclonal Antibodies
HuCAL Custom Monoclonal HuCAL Custom Monoclonal Antibodies Highly Specific, Recombinant Antibodies in 8 Weeks Highly Specific Monoclonal Antibodies in Just 8 Weeks HuCAL PLATINUM (Human Combinatorial Antibody
More informationImmunoglobulin E (IgE) concentrations in Human. Immunoglobulin E (IgE) Human ELISA Kit
ab108650 Immunoglobulin E (IgE) Human ELISA Kit Instructions for Use For the quantitative measurement of Immunoglobulin E (IgE) concentrations in Human serum. This product is for research use only and
More informationThe Number of Elevated Cytokines and Chemokines in Preclinical Seropositive Rheumatoid Arthritis Predicts Time to Diagnosis in an Age-Dependent Manner
ARTHRITIS & RHEUMATISM Vol. 62, No. 11, November 2010, pp 3161 3172 DOI 10.1002/art.27638 2010, American College of Rheumatology The Number of Elevated Cytokines and Chemokines in Preclinical Seropositive
More informationHow To Determine The Level Of Interleukin 16
The Egyptian Journal of Hospital Medicine Vol., 20: 46 57 September 2005 I.S.S.N: 12084 1687 2002 Interleukin-10, Interleukin- 16 and Interferon-γ in serum of patients with rheumatoid arthritis and correlation
More informationArthritis encompasses at least 100 distinct
RHEUMATOID ARTHRITIS: DISEASE PATHOGENESIS * Assil Saleh, MD, MPH ABSTRACT Rheumatoid arthritis (RA) is a common chronic inflammatory disorder with destructive and systemic consequences. The disease is
More informationHuman Free Testosterone(F-TESTO) ELISA Kit
Human Free Testosterone(F-TESTO) ELISA Kit Catalog Number. MBS700040 For the quantitative determination of human free testosterone(f-testo) concentrations in serum, plasma. This package insert must be
More informationRheumatoid Arthritis. Outline. Treatment Goal 4/10/2013. Clinical evaluation New treatment options Future research Discussion
Rheumatoid Arthritis Robert L. Talbert, Pharm.D., FCCP, BCPS University of Texas at Austin College of Pharmacy University of Texas Health Science Center at San Antonio Outline Clinical evaluation New treatment
More informationDevelopments on the physiopathology of rheumatoid arthritis, Time for a new theory?
Review Developments on the physiopathology of rheumatoid arthritis, Time for a new theory? María Guadalupe Zavala-Cerna 1, Mario Salazar-Páramo 2, Arnulfo Nava 3 * 1 Medical research unit in Clinical Epidemiology,
More informationEarly Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis
Early Diagnosis of Rheumatoid Arthritis & Axial Spondyloarthritis 奇 美 醫 院 過 敏 免 疫 風 濕 科 陳 宏 安 Rheumatoid arthritis Most common chronic inflammatory joint disease Multisystem autoimmune disease of unknown
More informationThe Vectra DA Test for Rheumatoid Arthritis
Medical Policy Manual Topic: Vectra DA Blood Test for Rheumatoid Arthritis Date of Origin: June 2014 Section: Laboratory Last Reviewed Date: May 2015 Policy No: 67 Effective Date: July 1, 2015 IMPORTANT
More informationSummary & Conclusion
The prognostic value of angiogenesis markers in patients with non-hodgkin lymphoma. Summary & Conclusion The current study aims to asses the prognostic value of some angiogenesis markers in patients with
More informationCytokines pattern of Multiple Sclerosis patients treated with Apitherapy
Cytokines pattern of Multiple Sclerosis patients treated with Apitherapy Ahmad G. Hegazi, Khaled Al- Menabbawy, Eman H. Abd El- Rahman and Suzette I. Helal National Research Center, Dokki, Giza, Egypt
More informationThe antiinflammatory action mechanism of an antihomotoxic composita remedy
The antiinflammatory action mechanism of an antihomotoxic composita remedy H. Heine, F. Andrä [Ärztezeitschrift für Naturheilverfahren 43, 2 (22)] [Summary] Introduction In order to use preparations in
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) September 2014 Review date: September 2017 Bulletin 203: Tocilizumab (subcutaneous) in combination with methotrexate or as monotherapy for the treatment
More information